Table 2.

Clinical outcomes among patients with asthma (N = 142) switching from pressurized metered dose inhaler (pMDI) to dry powder inhaler (DPI)*

Outcome parameter	Baseline visit (pMDI)	12-week visit (DPI)	p value
ACT† mean (95% CI)	13.3 (12.7–13.9)	21.0 (20.6–21.5)	< .0001
FEV1% mean (95% CI)	76.7 (73.8–79.6)	87.1 (84.1–90.0)	< .0001
Mini-AQLQ‡ mean (95% CI)	55.1 (53.0–57.2)	78.2 (76.2–80.3)	< .0001
Reliever use, N (%)§			< .0001
never	12 (8.6)	56 (39.7)	< .0001
≤ 1 per week	13 (9.3)	72 (51.1)
2–3 times per week	54 (38.6)	12 (8.5)
1–2 times per day	48 (34.3)	1 (0.7)
≥ 3 times per day	13 (9.3)	0
Reliever use per day median (min, max) §	0.4 (0.0–3.0)	0.1 (0.0–1.5)

CI confidence interval

^*DPI used in the study was budesonide–formoterol Easyhaler

^†Asthma Control Test (ACT) scores: ≤ 15 very poorly controlled; 16–19 not well controlled, and > 20 well controlled. The minimum clinically important difference is 3 points [16]

^‡Mini Asthma Quality of Life Questionnaire (mini-AQLQ) scores: a score < 4, indicating very limited daily life due to asthma. The minimum clinically important difference is ≥ 0.5 points [19]

^§Data on reliever medication at baseline visit missing for two patients, and for the 12-week visit for one patient. Reliever medication use (RM) median, and range estimated as follows: never then RM = 0; ≤ 1 per week then RM = 1 per week; 2–3 times per week then RM = 2.5 per week; 1–2 times per day then RM = 1.5 per day; ≥ 3times per day then RM = 3 per day